Nov 13, 2024 07:00AM
Aug 15, 2024 06:16AM
Aug 14, 2024 07:05AM
Aug 14, 2024 07:00AM
Aug 14, 2024 07:00AM
May 23, 2024 07:29AM
May 9, 2024 04:05PM Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Apr 15, 2024 08:01AM
Apr 15, 2024 08:00AM
Apr 1, 2024 08:30AM
Mar 21, 2024 04:32PM
Mar 21, 2024 04:30PM
Mar 7, 2024 04:05PM
Feb 29, 2024 08:00AM Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial
Jan 17, 2024 08:00AM
Jan 4, 2024 08:12AM
Jan 4, 2024 08:00AM
Dec 12, 2023 08:04AM
Dec 12, 2023 08:00AM
Dec 4, 2023 08:31AM
Dec 4, 2023 08:30AM Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Leve
Nov 9, 2023 08:30AM
Oct 4, 2023 07:07AM
Oct 4, 2023 07:00AM
Aug 14, 2023 08:00AM
Jan 19, 2023 08:30AM
Nov 10, 2022 04:05PM
Sep 7, 2022 09:07AM Viracta Therapeutics (VIRX) Announces Orphan Drug Designation Granted by the European Commission for Nana-val for the Treatment of Peripheral T-cell Lymphoma
Sep 7, 2022 09:00AM
Mar 16, 2022 08:30AM
Nov 29, 2021 08:01AM
Nov 29, 2021 08:00AM
Nov 10, 2021 08:00AM
Aug 12, 2021 08:00AM
Jul 21, 2021 08:02AM Viracta Therapeutics (VIRX) Announces FDA Clearance of IND Application for Phase 1b/2 Trial in Epstein-Barr Virus-Positive Solid Tumors
Jul 21, 2021 08:00AM

322,898 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All